Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. - Wikidata - wikimedia - TriplyDB

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

http://www.wikidata.org/entity/Q43086102

about

Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy NK cells in therapy of cancer CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Natural killer cell therapy in children with relapsed leukemia.Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Combination immune therapies to enhance anti-tumor responses by NK cells.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Role of Natural Killer Cells in HIV-Associated Malignancies.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Clinical utility of natural killer cells in cancer therapy and transplantation.Update on antigen-specific immunotherapy of acute myeloid leukemia.Therapeutic potential and challenges of natural killer cells in treatment of solid tumors Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.The antileukemic potential of natural killer cells.Cytokine secretion and NK cell activity in human ADAM17 deficiency.Advances in clinical NK cell studies: Donor selection, manufacturing and quality control Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.Acute myeloid leukemia targets for bispecific antibodies.Fcγ Receptor Heterogeneity in Leukocyte Functional Responses.Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

P2860

Q26751011-F146703C-E737-4874-9F03-D4DF038C88F1 Q26765115-0FACEDC2-9DC6-4514-8F8A-D863DFFF9595 Q26771449-ED36D951-DF89-45E0-A718-1FB1BF394963 Q26773135-1C499368-50B0-4BF7-A405-86D12529FFD0 Q26774678-75815D37-F57D-4F3D-B303-0FCA35BBF079 Q26797345-B5DA9FA5-E37F-4F3D-AFC1-4AC26011F8A9 Q28242241-AEDDE859-E9E6-4A00-BFCC-2F7E3F9B24DC Q33585293-D2098D2B-16B2-4A5B-9DC4-5F5D163A5FDA Q33770125-BB874B4D-AF8C-4EA9-8870-27F8220595AF Q34483504-20FBE068-7BB9-4796-B959-00866987491B Q34550963-4862CE87-421E-4BD4-82CB-597D64583248 Q34551199-B9B8A372-8463-4251-8E87-A76409AF7E42 Q35130286-6942DE38-C99C-4611-80E3-AB12000AA443 Q35146288-08B9B1AB-00A1-46A9-85CC-788FBBDBD6C4 Q35252186-5606D636-415C-44FB-9185-5E550B895ABE Q35546759-219309D1-13BE-42A7-8643-E55D087A00F9 Q35588890-348BA9AE-FC63-4BA1-8DCF-976F99C422C0 Q35600095-A7CC61CE-FA76-4DA0-9BD1-1575FE2624D1 Q36251948-90F0F714-8B36-4B9F-BD2C-A7E4560FF7EA Q36739038-C69EDCB7-4BC6-4201-922C-9B63889587FA Q37376659-D60BB8B2-7373-413B-B67D-88B030F75B4F Q37408550-920B3E33-A947-42C4-91ED-1736F600993D Q37589671-53C04CAD-8077-4A97-9E39-CDE80D945661 Q37712593-8128F741-45C2-43BD-97DD-38FAF757FE4B Q37723469-56F50412-F309-4F7A-9A3A-8D89991B987D Q38195120-41E0190C-D549-40DE-B1D4-6B004929B57D Q38432103-43D1D1B8-891D-464F-9B01-37EBBF3BE053 Q38478878-A1F2D468-B4F6-4C92-864D-355E3274CF3B Q38522618-14330BF8-055E-42D3-989D-FC7190001BE6 Q38542034-BD13995E-F3FF-45D9-B982-11AEB6E08C57 Q38599353-6164FF8A-7C1B-4F77-8354-D4B7FFF0C4C5 Q38723957-1696F732-4C41-4AF9-8B91-6E77113A8321 Q38773351-0208296D-5B6B-4B83-A36C-6E7953B96560 Q38810631-9B620076-5690-4AF4-9F4B-F185A8D01B7B Q38824360-99489E67-63B8-486A-ABEC-5BE28613DD11 Q38849985-6B5684CA-4B64-4D32-9F71-1C984FDE576D Q38930242-ED7F2D28-0E56-43E0-85AD-AFA9F9C9EB60 Q39117761-7B8A375F-1D86-4832-A692-1D85526882D2 Q39217862-2C909468-ED2A-4F8A-92AB-82DB5A6EA2D9 Q39296861-45E0834C-DFA8-4306-9B0A-878E1B373128

P2860

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

http://www.wikidata.org/entity/Q43086102

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@en

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@nl

type

label

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@en

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@nl

prefLabel

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@en

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@nl

P1433

Q43086102-1EF9B01C-0E9F-465D-8F7D-61D438EFD984

P1476

Q43086102-88A60652-8950-4A3D-A593-2CE4842CCF57

P2093

Q43086102-0F84D93B-C0E9-4D7F-A0CC-188CE0501547

Q43086102-13A817EC-815F-488D-BF92-0D478C537F16

Q43086102-2373BD8C-709C-46D7-BBD4-ABA4B6E35625

Q43086102-45D638C6-9EC2-4FDA-A0E4-4F8E07FCD5A3

Q43086102-545A0AE7-4ECD-491D-B02A-03E7B1A5294A

Q43086102-56226448-1A1F-45C3-AC1B-B1E8BDC9A74C

Q43086102-616D496E-248C-4421-A8FB-07081C26534D

Q43086102-9F87E118-A4B8-4375-9550-7AC2BD1CB852

Q43086102-AEACDE90-EF95-4EE4-9C62-8D0872E161C5

Q43086102-C8B70106-3C9D-471A-AD5D-C97F255F1FD0

P2860

Q43086102-00965C24-2FE7-4E01-92BF-0BBF1A315D9F

Q43086102-0BE8C385-DBFC-41B9-BBC8-A96CF626C67A

Q43086102-0D3ABC8B-7652-416B-AC5B-28468B4D0C77

Q43086102-0F04C4A0-10AD-40A5-A550-900BF1ADD7D6

Q43086102-18EFDD3D-B335-48BE-8C2D-32E217269237

Q43086102-22EA9CD8-FBFF-4513-A2C7-CFEE6C72D12F

Q43086102-3E522FE3-CFB6-475F-8CF1-5DB29DE72F1D

Q43086102-3F4E8056-684B-40AB-AE5E-EDC54EACFF0B

Q43086102-4CEA366A-FD04-475E-8457-DABA03A6DECB

Q43086102-5EF53E02-BA0A-4155-AFCD-FAD04A8389D7

P304

Q43086102-2AA79E9C-5E46-47EB-8F96-41114229103E

P31

Q43086102-DBE59BBF-A26F-4FCE-B09D-61ED26E54615

P356

Q43086102-5F78E351-3839-4893-A981-C2EA82A2E945

P407

Q43086102-B9A363B2-EB44-47AB-B92C-F618E312FD9D

P433

Q43086102-61D31C2B-D9F9-4531-A8D8-282881081E9B

P478

Q43086102-30930993-E33A-4FD2-9BF6-93D82F3579D1

P50

Q43086102-9CC0D45A-4603-424B-AA32-D4AA465DE975

P577

Q43086102-B4708EFE-F764-4A54-9FBB-73EE380AD7C8

P698

Q43086102-D502B471-DB1B-428C-8BB7-E316BAA2C57D

P921

Q43086102-A8482B9A-776E-4622-A3FE-BFAF8DCAE94E

P932

Q43086102-F2749CEE-160E-4567-A4B9-EC2279DC3938

P356

1078-0432.CCR-13-0505

P1433

Clinical Cancer Research

P1476

Targeting natural killer cells ...... engager and ADAM17 inhibition.

@en

P2093

Andres Wiernik

http://www.w3.org/2001/XMLSchema#string

Bin Zhang

http://www.w3.org/2001/XMLSchema#string

Bree Foley

http://www.w3.org/2001/XMLSchema#string

Bruce Walcheck

http://www.w3.org/2001/XMLSchema#string

Daniel A Vallera

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

Erica Warlick

http://www.w3.org/2001/XMLSchema#string

Julie A Ross

http://www.w3.org/2001/XMLSchema#string

Michael R Verneris

http://www.w3.org/2001/XMLSchema#string

Michelle K Gleason

http://www.w3.org/2001/XMLSchema#string

P2860

A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

In search of the 'missing self': MHC molecules and NK cell recognition

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo

NK cell recognition

Fcgamma receptors as regulators of immune responses

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.

P304

3844-3855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0505

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey S. Miller

P577

2013-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23690482

http://www.w3.org/2001/XMLSchema#string

P921

P932

3715574

http://www.w3.org/2001/XMLSchema#string